Abstract
Objectives
The exact underlying mechanism of developing diabetes-related cardiovascular disease (CVD) among patients with type 2 diabetes (T2D) is not clear. Metabolomics can provide a platform enabling the prediction, diagnosis, and understanding of the risk of CVD in patients with diabetes mellitus. The aim of this review is to summarize the available evidence on the relationship between metabolomics and cardiovascular diseases in patients with diabetes.
Methods
The literature was searched to find out studies that have investigated the relationship between the alteration of specific metabolites and cardiovascular diseases in patients with diabetes.
Results
Evidence proposed that changes in the metabolism of certain amino acids, lipids, and carbohydrates, independent of traditional CVD risk factors, are associated with increased CVD risk.
Conclusions
Metabolomics can provide a platform to enable the prediction, diagnosis, and understanding of the risk of CVD in patients with diabetes mellitus. The association of the alteration in specific metabolites with CVD may be considered in the investigations for the development of new therapeutic targets for the prevention of CVD in patients with diabetes mellitus.
Similar content being viewed by others
References
Tabish SA. Is diabetes becoming the biggest epidemic of the twenty-first century? Int J health Sci. 2007;1(2):V.
International Diabetes Federation. IDF Diabetes Atlas, 10th ed. ; 2021. https://diabetesatlas.org/atlas/tenth-edition/.
Moradi-Lakeh M, El Bcheraoui C, Khalil I, Charara R, Afshin A, Wang H, et al. Diabetes mellitus and chronic kidney disease in the Eastern Mediterranean Region: findings from the global burden of Disease 2015 study. Int J Public Health. 2018;63(1):177–86.
Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141(6):421–31.
Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabetes Care. 1998;21(7):1167–72.
Low Wang CC, Hess CN, Hiatt WR, Goldfine AB. Clinical update: Cardiovascular Disease in Diabetes Mellitus: atherosclerotic Cardiovascular Disease and Heart failure in type 2 diabetes Mellitus - Mechanisms, Management, and clinical considerations. Circulation. 2016;133(24):2459–502.
Mohammadi E, Morasa FS, Roshani S, Rezaei N, Azadnajafabad S, Moghaddam SS, et al. Estimating the attributable risk of vascular disorders in different ranges of fasting plasma glucose and assessing the effectiveness of anti-diabetes agents on risk reduction; questioning the current diagnostic criteria. J Diabetes Metab Disord. 2020;19(2):1423–30.
Farzadfar F, Naghavi M, Sepanlou S, Saeedi Moghaddam S, Dangel W, Weaver N et al. Health system performance in Iran: a systematic analysis for the global burden of Disease Study 2019. The Lancet. 2022;399.
Magnusson M, Lewis GD, Ericson U, Orho-Melander M, Hedblad B, Engström G, et al. A diabetes-predictive amino acid score and future cardiovascular disease. Eur Heart J. 2013;34(26):1982–9.
Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57.
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57.
Croyal M, Saulnier PJ, Aguesse A, Gand E, Ragot S, Roussel R et al. Plasma trimethylamine N-Oxide and risk of Cardiovascular events in patients with type 2 diabetes. J Clin Endocrinol Metab. 2020;105(7).
Harris K, Oshima M, Sattar N, Würtz P, Jun M, Welsh P, et al. Plasma fatty acids and the risk of vascular disease and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE study. Diabetologia. 2020;63(8):1637–47.
Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG, Kell DB. Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 2004;22(5):245–52.
Au A. Metabolomics and lipidomics of ischemic stroke. Adv Clin Chem. 2018;85:31–69.
Bingol K. Recent advances in targeted and untargeted metabolomics by NMR and MS/NMR methods. High-Throughput. 2018;7(2):9.
Vinayavekhin N, Saghatelian A. Untargeted metabolomics. Curr Protoc Mol Biol. 2010;90(1):30. 1-.1. 24.
Letertre MP, Giraudeau P, De Tullio P. Nuclear magnetic resonance spectroscopy in clinical metabolomics and personalized medicine: current challenges and perspectives. Front Mol Biosci. 2021;8.
Zhang A, Sun H, Wang P, Han Y, Wang X. Modern analytical techniques in metabolomics analysis. Analyst. 2012;137(2):293–300.
Emwas A-H, Roy R, McKay RT, Tenori L, Saccenti E, Gowda GN, et al. NMR spectroscopy for metabolomics research. Metabolites. 2019;9(7):123.
Lutz NW, Bernard M. Methodological developments for metabolic NMR spectroscopy from cultured cells to tissue extracts: achievements, Progress and Pitfalls. Molecules. 2022;27(13):4214.
Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007;2(11):2692–703.
Letertre MPM, Dervilly G, Giraudeau P. Combined Nuclear magnetic resonance spectroscopy and Mass Spectrometry Approaches for Metabolomics. Anal Chem. 2021;93(1):500–18.
Trivedi DK, Iles RK. Do not just do it, do it right: urinary metabolomics–establishing clinically relevant baselines. Biomed Chromatogr. 2014;28(11):1491–501.
Chen ZZ, Gerszten RE. Metabolomics and proteomics in type 2 diabetes. Circ Res. 2020;126(11):1613–27.
Suhre K, Meisinger C, Döring A, Altmaier E, Belcredi P, Gieger C, et al. Metabolic footprint of diabetes: a multiplatform Metabolomics Study in an epidemiological setting. PLoS ONE. 2010;5(11):e13953.
Kimura T, Noguchi Y, Shikata N, Takahashi M. Plasma amino acid analysis for diagnosis and amino acid-based metabolic networks. Curr Opin Clin Nutr Metab Care. 2009;12(1):49–53.
McGarrah RW, Crown SB, Zhang GF, Shah SH, Newgard CB. Cardiovascular Metabolomics. Circ Res. 2018;122(9):1238–58.
Ruiz-Canela M, Toledo E, Clish CB, Hruby A, Liang L, Salas-Salvadó J, et al. Plasma branched-chain amino acids and Incident Cardiovascular Disease in the PREDIMED Trial. Clin Chem. 2016;62(4):582–92.
Kume S, Araki S-i, Ono N, Shinhara A, Muramatsu T, Araki H, et al. Predictive Properties of plasma amino Acid Profile for Cardiovascular Disease in patients with type 2 diabetes. PLoS ONE. 2014;9(6):e101219.
White PJ, McGarrah RW, Herman MA, Bain JR, Shah SH, Newgard CB. Insulin action, type 2 diabetes, and branched-chain amino acids: a two-way street. Mol Metab. 2021;52:101261.
Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2007;30(7):1834–9.
Lim YJ, Sidor NA, Tonial NC, Che A, Urquhart BL. Uremic toxins in the progression of chronic kidney disease and cardiovascular disease: mechanisms and therapeutic targets. Toxins. 2021;13(2):142.
Krzyzanowska K, Mittermayer F, Krugluger W, Schnack C, Hofer M, Wolzt M, et al. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis. 2006;189(1):236–40.
Lajer M, Tarnow L, Jorsal A, Teerlink T, Parving H-H, Rossing P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts Cardiovascular Morbidity and Mortality in Type 1 Diabetic Patients with Diabetic Nephropathy. Diabetes Care. 2008;31(4):747–52.
Ma J, Folsom AR, Shahar E, Eckfeldt JH. Plasma fatty acid composition as an indicator of habitual dietary fat intake in middle-aged adults. The atherosclerosis risk in Communities (ARIC) Study investigators. Am J Clin Nutr. 1995;62(3):564–71.
Hafizi Abu Bakar M, Kian Kai C, Wan Hassan WN, Sarmidi MR, Yaakob H, Zaman Huri H. Mitochondrial dysfunction as a central event for mechanisms underlying insulin resistance: the roles of long chain fatty acids. Diabetes Metab Res Rev. 2015;31(5):453–75.
Hosseinkhani S, Salari P, Bandarian F, Asadi M, Shirani S, Najjar N, et al. Circulating amino acids and acylcarnitines correlated with different CAC score ranges in diabetic postmenopausal women using LC–MS/MS based metabolomics approach. BMC Endocr Disord. 2022;22(1):1–9.
Harris K, Muntner P, Woodward M, Jun M, Oshima M, Gong J et al. Clinical outcomes by atherosclerotic cardiovascular disease risk score and blood pressure level in high risk individuals with type 2 diabetes. J Hum Hypertens. 2022.
Knottnerus SJ, Bleeker JC, Wüst RC, Ferdinandusse S, IJlst L, Wijburg FA, et al. Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle. Rev Endocr Metab Disord. 2018;19(1):93–106.
Sun L, Liang L, Gao X, Zhang H, Yao P, Hu Y, et al. Early prediction of developing type 2 diabetes by plasma acylcarnitines: a Population-Based study. Diabetes Care. 2016;39(9):1563–70.
Hosseinkhani S, Emamgholipour S, Salari P, Khalagi K, Shirani S, Najjar N, et al. Evaluating the association between amino acid and acylcarnitine profiles and different levels of coronary artery disease risk in postmenopausal women using targeted metabolomics technique. Menopause. 2022;29(9):1062–70.
Karagiannidis E, Moysidis DV, Papazoglou AS, Panteris E, Deda O, Stalikas N, et al. Prognostic significance of metabolomic biomarkers in patients with diabetes mellitus and coronary artery disease. Cardiovasc Diabetol. 2022;21(1):1–10.
Slotte JP. Biological functions of sphingomyelins. Prog Lipid Res. 2013;52(4):424–37.
Chen Y, Jia H, Qian X, Wang J, Yu M, Gong Q, et al. Circulating Palmitoyl Sphingomyelin is Associated with Cardiovascular Disease in individuals with type 2 diabetes: findings from the China Da Qing diabetes study. Diabetes Care. 2022;45(3):666–73.
Ferreira-Divino LF, Suvitaival T, Rotbain Curovic V, Tofte N, Trošt K, Mattila IM, et al. Circulating metabolites and molecular lipid species are associated with future cardiovascular morbidity and mortality in type 1 diabetes. Cardiovasc Diabetol. 2022;21(1):1–10.
Pongrac Barlovic D, Harjutsalo V, Sandholm N, Forsblom C, Groop PH. Sphingomyelin and progression of renal and coronary heart disease in individuals with type 1 diabetes. Diabetologia. 2020;63(9):1847–56.
Park T-S, Goldberg IJ. Sphingolipids, lipotoxic cardiomyopathy, and cardiac failure. Heart Fail Clin. 2012;8(4):633–41.
Jiang X-c, Paultre F, Pearson TA, Reed RG, Francis CK, Lin M, et al. Plasma sphingomyelin level as a risk factor for coronary artery disease. Arterioscler Thromb Vasc Biol. 2000;20(12):2614–8.
Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119(5):10–S6.
van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim et Biophys Acta (BBA) - Biomembr. 2017;1859(9, Part B):1558–72.
Reiss D, Beyer K, Engelmann B. Delayed oxidative degradation of polyunsaturated diacyl phospholipids in the presence of plasmalogen phospholipids in vitro. Biochem J. 1997;323(3):807–14. (Pt 3)(Pt.
van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochim Biophys Acta Biomembr. 2017;1859(9 Pt B):1558–72.
Stratmann B, Richter K, Wang R, Yu Z, Xu T, Prehn C, et al. Metabolomic signature of coronary artery disease in type 2 diabetes Mellitus. Int J Endocrinol. 2017;2017:7938216.
Hartiala J, Bennett BJ, Tang WH, Wang Z, Stewart AF, Roberts R, et al. Comparative genome-wide association studies in mice and humans for trimethylamine N-oxide, a proatherogenic metabolite of choline and L-carnitine. Arterioscler Thromb Vasc Biol. 2014;34(6):1307–13.
Schiattarella GG, Sannino A, Toscano E, Giugliano G, Gargiulo G, Franzone A, et al. Gut microbe-generated metabolite trimethylamine-N-oxide as cardiovascular risk biomarker: a systematic review and dose-response meta-analysis. Eur Heart J. 2017;38(39):2948–56.
Witkowski M, Weeks TL, Hazen SL. Gut microbiota and cardiovascular disease. Circ Res. 2020;127(4):553–70.
Tang WH, Wang Z, Kennedy DJ, Wu Y, Buffa JA, Agatisa-Boyle B, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–55.
Croyal M, Saulnier P-J, Aguesse A, Gand E, Ragot S, Roussel R, et al. Plasma trimethylamine N-Oxide and risk of Cardiovascular events in patients with type 2 diabetes. J Clin Endocrinol Metab. 2020;105(7):2371–80.
Flores-Guerrero JL, van Dijk PR, Connelly MA, Garcia E, Bilo HJG, Navis G, et al. Circulating trimethylamine N-Oxide is Associated with increased risk of Cardiovascular Mortality in Type-2 diabetes: results from a dutch diabetes cohort (ZODIAC-59). J Clin Med. 2021;10(11):2269.
Cardona A, O’Brien A, Bernier MC, Somogyi A, Wysocki VH, Smart S, et al. Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis. BMJ Open Diabetes Research and Care. 2019;7(1):e000718.
Winther SA, Øllgaard JC, Hansen TW, von Scholten BJ, Reinhard H, Ahluwalia TS, et al. Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria. PLoS ONE. 2021;16(3):e0244402.
Jia J, Dou P, Gao M, Kong X, Li C, Liu Z, et al. Assessment of Causal Direction between Gut Microbiota–Dependent Metabolites and Cardiometabolic Health: a bidirectional mendelian randomization analysis. Diabetes. 2019;68(9):1747–55.
Festa A, Williams K, Hanley AJG, Otvos JD, Goff DC, Wagenknecht LE, et al. Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the insulin resistance atherosclerosis study. Circulation. 2005;111(25):3465–72.
Camont L, Chapman MJ, Kontush A. Biological activities of HDL subpopulations and their relevance to cardiovascular disease. Trends Mol Med. 2011;17(10):594–603.
Camont L, Lhomme M, Rached F, Le Goff W, Nègre-Salvayre A, Salvayre R, et al. Small, dense high-density lipoprotein-3 particles are enriched in negatively charged phospholipids: relevance to cellular cholesterol efflux, antioxidative, antithrombotic, anti-inflammatory, and antiapoptotic functionalities. Arterioscler Thromb Vasc Biol. 2013;33(12):2715–23.
Soedamah-Muthu SS, Chang YF, Otvos J, Evans RW, Orchard TJ. Lipoprotein subclass measurements by nuclear magnetic resonance spectroscopy improve the prediction of coronary artery disease in type 1 diabetes. A prospective report from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetologia. 2003;46(5):674–82.
Alshehry ZH, Mundra PA, Barlow CK, Mellett NA, Wong G, McConville MJ, et al. Plasma lipidomic profiles improve on traditional risk factors for the Prediction of Cardiovascular events in type 2 diabetes Mellitus. Circulation. 2016;134(21):1637–50.
Cardona A, O’Brien A, Bernier MC, Somogyi A, Wysocki VH, Smart S, et al. Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis. BMJ Open Diabetes Res Care. 2019;7(1):e000718.
Huang Z, Klaric L, Krasauskaite J, McLachlan S, Strachan MW, Wilson JF, et al. Serum metabolomic profiles associated with subclinical and clinical cardiovascular phenotypes in people with type 2 diabetes. Cardiovasc Diabetol. 2022;21(1):1–10.
Lim LL, Lau ES, Fung E, Lee HM, Ma RC, Tam CH, et al. Circulating branched-chain amino acids and incident heart failure in type 2 diabetes: the Hong Kong Diabetes Register. Diabetes/Metab Res Rev. 2020;36(3):e3253.
Ottosson F, Smith E, Fernandez C, Melander O. Plasma metabolites associate with all-cause mortality in individuals with type 2 diabetes. Metabolites. 2020;10(8):315–25.
Welsh P, Rankin N, Li Q, Mark PB, Würtz P, Ala-Korpela M, et al. Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial. Diabetologia. 2018;61(7):1581–91.
Deda O, Panteris E, Meikopoulos T, Begou O, Mouskeftara T, Karagiannidis E, et al. Correlation of serum acylcarnitines with clinical presentation and severity of coronary artery disease. Biomolecules. 2022;12(3):354.
Li T, Luo HH, Feng XF, Bai Y, Fang ZZ, Wu GG, et al. Plasma free amino acids and risk of Cardiovascular Disease in chinese patients with type 2 diabetes. Front Endocrinol (Lausanne). 2020;11:519923.
Liu X, Gao J, Chen J, Wang Z, Shi Q, Man H, et al. Identification of metabolic biomarkers in patients with type 2 diabetic coronary heart diseases based on metabolomic approach. Sci Rep. 2016;6:30785.
Liu W, Guo P, Dai T, Shi X, Shen G, Feng J. Metabolic interactions and differences between Coronary Heart Disease and Diabetes Mellitus: a pilot study on Biomarker determination and pathogenesis. J Proteome Res. 2021;20(5):2364–73.
Zhao S, Feng XF, Huang T, Luo HH, Chen JX, Zeng J, et al. The Association between acylcarnitine metabolites and Cardiovascular Disease in chinese patients with type 2 diabetes Mellitus. Front Endocrinol (Lausanne). 2020;11:212.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declared that they have no conflict of interest.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Dodangeh, S., Taghizadeh, H., Hosseinkhani, S. et al. Metabolomics signature of cardiovascular disease in patients with diabetes, a narrative review. J Diabetes Metab Disord 22, 985–994 (2023). https://doi.org/10.1007/s40200-023-01256-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40200-023-01256-8